Agreement Provides for Complete Biomanufacturing Provision

Horizon Discovery Group plc has entered into a non-exclusive Licensing Agreement with ProteoNic B.V. to provide the CHOGUN expression vector to customers alongside Horizon’s HD-BIOP3 GS Null CHO cell line as standard, providing a complete biomanufacturing platform.

 Paul Morrill, President, Products at Horizon Discovery Group commented: “Horizon’s GS Null CHO cell line, generated through the Company’s gene editing platform, has undergone extensive validation to confirm its suitability for biomanufacturing.  By including ProteoNic’s powerful expression vector, we are now able to offer customers a complete platform that showcases the full capabilities of these cells.”

 Victor Schut, Chief Business Officer, ProteoNic said: “The CHOGUN vector has proven to be extremely effective in a variety of cell lines including Horizon’s GS Null CHO cell line.  We are excited to offer it to Horizon’s customers, providing another channel to access the 2G UNic technology for improved recombinant protein production. We believe that this platform is an attractive alternative for any other therapeutics, including biosimilars, producing system in the market today. We look forward to continuing to work together on future projects.”

 Financial details of the agreement were not disclosed